infographic

On Tuesday, Veru received FDA permission to initiate a phase 2 clinical trial to assess the efficacy of VERU-111 in combating COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2. Veru has initiated the study and expects the first patient to be dosed within 2 weeks...

Pfizer posted a 1% improvement in revenues of $12.9 billion for the first quarter of 2018. Reported net income jumped 14% to $3.5 billion, while adjusted net income grew 11% to $4.6 billion. Reported EPS rose 15% to $0.59, while adjusted EPS grew 12% to $0.77 compared to last year. While revenue...

In the third quarter, even as revenue jumped 7%, net earnings came crashing down by about 30%. Even their safely adjusted EPS fell 3%. It's been an up-and-down kind of year for Bristol-Myers Squibb. Early this year, we investors were concerned after BMY opted not to pursue accelerated approval...